Decreased Level of Cord Blood Circulating Endothelial Colony-Forming Cells in Preeclampsia

Hospital Universitario Virgen del Rocío, Hispalis, Andalusia, Spain
Hypertension (Impact Factor: 6.48). 04/2014; 64(1). DOI: 10.1161/HYPERTENSIONAHA.113.03058
Source: PubMed


Preeclampsia is a pregnancy-related disorder associated with increased cardiovascular risk for the offspring. Endothelial colony-forming cells (ECFCs) are a subset of circulating endothelial progenitor cells that participate in the formation of vasculature during development. However, the effect of preeclampsia on fetal levels of ECFCs is largely unknown. In this study, we sought to determine whether cord blood ECFC abundance and function are altered in preeclampsia. We conducted a prospective cohort study that included women with normal (n=35) and preeclamptic (n=15) pregnancies. We measured ECFC levels in the umbilical cord blood of neonates and characterized ECFC phenotype, cloning-forming ability, proliferation, and migration toward vascular endothelial growth factor-A and fibroblast growth factor-2, in vitro formation of capillary-like structures, and in vivo vasculogenic ability in immunodeficient mice. We found that the level of cord blood ECFCs was statistically lower in preeclampsia than in control pregnancies (P=0.04), a reduction that was independent of other obstetric factors. In addition, cord blood ECFCs from preeclamptic pregnancies required more time to emerge in culture than control ECFCs. However, once derived in culture, ECFC function was deemed normal and highly similar between preeclampsia and control, including the ability to form vascular networks in vivo. This study demonstrates that preeclampsia affects ECFC abundance in neonates. A reduced level of ECFCs during preeclamptic pregnancies may contribute to an increased risk of developing future cardiovascular events.

Download full-text


Available from: Rocío Muñoz-Hernández, Apr 24, 2014

  • No preview · Article · Apr 2014 · Hypertension
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Introduction: Endothelial colony-forming cells (ECFCs) are endothelial progenitors that circulate in peripheral blood and are currently the subject of intensive investigation due to their therapeutic potential. However, in adults, ECFCs comprise a very small subset among circulating cells, which makes their isolation a challenge. Materials and methods: Currently, the standard method for ECFC isolation relies on the separation of mononuclear cells and erythrocyte lysis, steps that are time consuming and known to increase cell loss. Alternatively, we previously developed a novel disposable microfluidic platform containing antibody-functionalized degradable hydrogel coatings that is ideally suited for capturing low-abundance circulating cells from unprocessed blood. In this study, we reasoned that this microfluidic approach could effectively isolate rare ECFCs by virtue of their CD34 expression. Results: We conducted preclinical experiments with peripheral blood from four adult volunteers and demonstrated that the actual microfluidic capture of circulating CD34(+) cells from unprocessed blood was compatible with the subsequent differentiation of these cells into ECFCs. Moreover, the ECFC yield obtained with the microfluidic system was comparable to that of the standard method. Importantly, we unequivocally validated the phenotypical and functional properties of the captured ECFCs, including the ability to form microvascular networks following transplantation into immunodeficient mice. Discussion: We showed that the simplicity and versatility of our microfluidic system could be very instrumental for ECFC isolation while preserving their therapeutic potential. We anticipate our results will facilitate additional development of clinically suitable microfluidic devices by the vascular therapeutic and diagnostic industry.
    Full-text · Article · Aug 2014 · Tissue Engineering Part C Methods
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Although emerging evidence demonstrates CEPC level increases in patients with solid tumors, it's still unknown whether the CEPCs can be cultured from patients with highly angiogenic RCC. The aim of this study was to culture and characterize the CEPCs from RCC patients. The level of CEPCs (% of CD45(-)CD34(+) VEGF-R2(+) cells in total PBMNCs) was quantified in 47 RCC patients and 40 HCs. PBMNCs were isolated from 33 RCC patients and 30 HCs for CEPC culture and characterization. The CEPC level was significantly higher in RCC patients than in HCs(0.276% vs 0.086%, p<0.001). The first emergence of CEPC colony was significantly earlier in RCC patients than in HCs (6.72d vs 14.67d, p<0.001). The success rate of CEPC culture (% of participates) and the number of CEPC colonies were significantly higher in RCC patients than in HCs (87.8% vs 40.0%,10.06 vs 1.83, respectively, each p<0.001). Positive correlation was found between the CEPC level and the number of CEPC colonies in RCC patients (r=0.762, p<0.001). CEPCs cultured from RCC patients and HCs demonstrated similar growth pattern, immunophenotype, ability to uptake AcLDL and bind lectin, and form capillary tubes in vitro. However, significantly higher number of VEGF-R2(+) CEPCs was found in RCC patients than in HCs (21.1% vs 13.4% , p<0.001). Earlier emergence of CEPC colonies, higher success rate of CEPC culture and higher number of CEPC colonies were found in RCC patients than in HCs. Results indicated the important significances of VEGF-R2(+) CEPCs in RCC patients. Copyright © 2015 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.
    Full-text · Article · Feb 2015 · The Journal of Urology
Show more